<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005268A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005268</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13980606</doc-number><date>20120118</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>BR</country><doc-number>PI1100663-3</doc-number><date>20110119</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>198</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>198</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>514562</main-classification></classification-national><invention-title id="d0e61">PHARMACEUTICAL COMPOSITION FOR TREATING OXIDATIVE STRESS-INDUCED PATHOLOGY AND USE THEREOF</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only"><addressbook><last-name>Peixoto</last-name><first-name>Eduardo Motta Alves</first-name><address><city>Sao Paulo</city><country>BR</country></address></addressbook><residence><country>BR</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Peixoto</last-name><first-name>Eduardo Motta Alves</first-name><address><city>Sao Paulo</city><country>BR</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/BR2012/000008</doc-number><kind>00</kind><date>20120118</date></document-id><us-371c124-date><date>20130920</date></us-371c124-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Pharmaceutical composition for treating oxidative stress induced pathology, comprising an association of the active ingredients methionine, cysteine and phenylalanine in association with at least one pharmaceutical excipient; said active ingredients being present in a methionine/phenylalanine molar ratio between 2.5 and 12.5; and in a methionine/cysteine molar ratio between 2 and 10.5; and the three active ingredients being present in free state, such as inner salt, or in the form of pharmaceutically acceptable salt; wherein said pharmaceutical composition is used for treating one of the oxidative stress induced pathologies, including intestinal system disorders, such as intestinal wall irritations, hemorrhoids of types 1, 2, 3 and 4 of Goligher classification. It is also disclosed the use of said composition in preparing a medication for treating oxidative stress induced pathology.</p></abstract></us-patent-application>